Argus raises target for Cencora stock from USD 340 to USD 380

Published on 10/21/2026 at 11:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cencora posted USD 84.8 billion in third-quarter revenue. Cencora stock costs EUR 304.85 on October 21, 2026, with November 4 results ahead.

Targets and operating figures

In a report dated October 20, 2026, Argus set a USD 380.00 target after USD 340.00.
Cencora reported USD 84.8 billion in third-quarter 2026 revenue.
Cencora stock traded at EUR 304.85 at 10:52 a.m. CEST at Lang & Schwarz on October 21, 2026.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora stock (ISIN US03073E1055) drew a new USD 380.00 target from Argus, up from USD 340.00 in a report dated October 20, 2026, according to MarketBeat. The same report cited a Buy rating, while Cencora's next results are scheduled for November 4, 2026.

What did Argus change?

Argus' target gives investors a fresh valuation reference after Cencora's fiscal third-quarter performance. The company reported adjusted earnings per share of USD 4.48 and revenue of USD 84.8 billion for the quarter, according to the Yahoo Finance transcript of the August 5, 2026 earnings call.

Management raised fiscal 2026 adjusted earnings-per-share guidance to USD 17.75-17.95 from USD 17.70-17.90. Adjusted operating income grew 17 percent in the third quarter, while revenue increased 5 percent, making the guidance change the central operating comparison for the stock.

Three dated Cencora events

On August 5, 2026, Cencora reported third-quarter revenue of USD 84.8 billion and raised its adjusted earnings-per-share outlook, as detailed by Yahoo Finance. On October 2, 2026, Cencora announced that it would publish fiscal fourth-quarter results on November 4, 2026, according to Yahoo Finance. On October 20, 2026, Argus raised its target from USD 340.00 to USD 380.00, as reported by MarketBeat.

When are the next results?

Cencora plans to release fiscal fourth-quarter and full-year 2026 results before the New York Stock Exchange opens on November 4, 2026, followed by an 8:30 a.m. ET conference call, according to Yahoo Finance. That report will test whether the 17.75-17.95 adjusted earnings-per-share range remains supported by the 5 percent third-quarter revenue growth.

Stock price and investor view

Cencora provides pharmaceutical distribution, commercialization, patient access, and pharmacy solutions across healthcare markets. Its fiscal third-quarter figures combine 5 percent revenue growth with 17 percent adjusted operating-income growth, while the higher Argus target places attention on execution ahead of the November report.

Cencora was trading intraday at EUR 304.85 at Lang & Schwarz on October 21, 2026 at 10:52 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.